Sculptor Capital’s Eucrates Biomedical Acquisition Corp. Warrant EUCRW Stock Holding History

Sculptor Capital’s Portfolio EUCRW Stock Details EUCRW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-25,881	Closed	-$935	–	606
2023 Q1	$935	Hold	25,881	–	–	﹤0.01%	527
2022 Q4	$1.71K	Sell	25,881 -500	-2%	-$18	﹤0.01%	777
2022 Q3	$1K	Hold	26,381	–	–	﹤0.01%	1074
2022 Q2	$1K	Buy	+26,381	New	+$4.24K	﹤0.01%	1148

Sculptor Capital's EUCRW Position: Q2 2023 in Review

Sculptor Capital sold out of Eucrates Biomedical Acquisition Corp. Warrant (EUCRW) in Q2 2023, closing a stake of 25,881 shares — an estimated $935 sold.

Sculptor Capital first reported a position in EUCRW in Q2 2022 and held it in 4 quarters. The position peaked at $1.71K in Q4 2022. 0 funds tracked by Wall St. Rank hold EUCRW as of Q2 2023.

Sculptor Capital reported no remaining Eucrates Biomedical Acquisition Corp. Warrant position as of Q2 2023 after selling out during the quarter.
Sculptor Capital sold 25,881 Eucrates Biomedical Acquisition Corp. Warrant shares in Q2 2023, an estimated $935.
Sculptor Capital first reported a position in Eucrates Biomedical Acquisition Corp. Warrant in Q2 2022 and held it in 4 quarters.
Sculptor Capital's Eucrates Biomedical Acquisition Corp. Warrant position peaked at $1.71K in Q4 2022.
0 funds tracked by Wall St. Rank held Eucrates Biomedical Acquisition Corp. Warrant as of Q2 2023.

Based on Sculptor Capital's 13F filing for Q2 2023, filed 14 Aug 2023.